Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Insider Sells 1,177 Shares of Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) insider Lai Wang sold 1,177 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $266.40, for a total value of $313,552.80. Following the transaction, the insider now owns 470 shares in the company, valued at $125,208. This trade represents a 71.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Lai Wang also recently made the following trade(s):

• On Tuesday, June 17th, Lai Wang sold 470 shares of BeOne Medicines stock. The shares were sold at an average price of $251.37, for a total transaction of $118,143.90.
• On Friday, June 6th, Lai Wang sold 1,402 shares of BeOne Medicines stock. The stock was sold at an average price of $252.39, for a total transaction of $353,850.78.

BeOne Medicines Trading Down 0.5%

Shares of ONC stock traded down $1.31 during trading hours on Wednesday, reaching $252.78. The company's stock had a trading volume of 230,441 shares, compared to its average volume of 447,828. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. The business's fifty day moving average is $243.44. The company has a market capitalization of $27.69 billion, a PE ratio of -67.95 and a beta of 0.30. BeOne Medicines Ltd. - Sponsored ADR has a one year low of $141.31 and a one year high of $287.88.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share for the quarter, beating analysts' consensus estimates of ($0.71) by $1.93. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. As a group, equities research analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ONC shares. Sanford C. Bernstein set a $259.00 target price on shares of BeOne Medicines in a report on Thursday, March 13th. JMP Securities set a $348.00 price target on shares of BeOne Medicines in a research report on Friday, February 28th. Wall Street Zen raised BeOne Medicines from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Bank of America raised BeOne Medicines from a "neutral" rating to a "buy" rating and boosted their target price for the company from $207.00 to $320.00 in a research note on Monday, March 3rd. Finally, Royal Bank Of Canada dropped their target price on BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, BeOne Medicines currently has an average rating of "Buy" and an average target price of $319.00.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.